U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Bradley LA, Palomaki G, Gutman S, et al. PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr. (Comparative Effectiveness Reviews, No. 98.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer

PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].

Show details

References

1.
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277–300. [PubMed: 20610543]
2.
Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012 Apr;30(2):195–200. [PubMed: 22476558]
3.
Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess. 2009;13:1–260. [PubMed: 19128541]
4.
Arcangeli S, Pinzi V, Arcangeli G. Epidemiology of prostate cancer and treatment remarks. World J Radiol. 2012 Jun 28;4(6):241–6. [PMC free article: PMC3391668] [PubMed: 22778875]
5.
National Comprehensive Cancer Network. Guidelines - Prostate Cancer Early Detection, Version I. 2011. www​.NCCN.org.
6.
Gronberg H. Prostate cancer epidemiology. Lancet. 2003 Mar 8;361(9360):859–64. [PubMed: 12642065]
7.
Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer. 2011 Mar 15;117(6):1123–35. [PubMed: 20960523]
8.
Ilic D, O'Connor D, Green S, et al. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 2011;107(6):882–91. [PubMed: 21392207]
9.
Yin M, Bastacky S, Chandran U, et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008 Mar;179(3):892–5. discussion 95. [PubMed: 18207193]
10.
SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008. seer​.cancer.gov/csr/1975_2005/
11.
Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–78. [PubMed: 12813170]
12.
Basch E, Oliver TK, Vickers A, et al. Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012 Jul 16 [PMC free article: PMC3776923] [PubMed: 22802323]
13.
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–61. [PubMed: 1707140]
14.
Bastian PJ, Carter BH, Bjartell A, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. European urology. 2009 Jun;55(6):1321–30. [PubMed: 19286302]
15.
Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. European urology. 2008 Aug;54(2):274–90. [PubMed: 18511177]
16.
Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int. 2011 Dec;108(11):1684–95. [PMC free article: PMC4086468] [PubMed: 22077546]
17.
Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer causes & control : CCC. 2008 Mar;19(2):175–81. [PMC free article: PMC3064270] [PubMed: 18027095]
18.
Boyle P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int. 2003 Aug;92(3):191–9. [PubMed: 12887466]
19.
Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Dec 6;155(11):762–71. [PubMed: 21984740]
20.
Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20;29(27):3669–76. [PubMed: 21825257]
21.
Moyer VAon behalf of the USPSTF. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012 Jul 17;157(2):120–34. [PubMed: 22801674]
22.
Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010. CA Cancer J Clin. 2011;60:70–98. PMID: [PubMed: 20200110]
23.
Prostate-Specific Antigen Best Practice Statement: 2009 Update. American Urological Association; www​.auanet.org/content/media/psa09.pdf.
24.
Rosenthal SA, Sandler HM. Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol. 2010 Jan;7(1):31–8. [PubMed: 20062072]
25.
Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19;98(8):529–34. [PubMed: 16622122]
26.
Amling CL, Catalona WJ, Klein EA. Deciding whom to biopsy. Urol Oncol. 2010 Sep-Oct;28(5):542–5. [PubMed: 20816613]
27.
Simmons MN, Berglund RK, Jones JS. A practical guide to prostate cancer diagnosis and management. Cleve Clin J Med. 2011;78(5):321–31. [PubMed: 21536828]
28.
Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001 Sep;166(3):856–60. [PubMed: 11490233]
29.
D' Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clincally localized prostate cancer. JAMA. 1998 Sep 16;280(11):969–74. [PubMed: 9749478]
30.
Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extert of nonpalpable (stage T1c) prostate cancer. Jama. 1994;271:368–74. PMID: [PubMed: 7506797]
31.
Perdona S, Cavadas V, Di Lorenzo G, et al. Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol. 2011 Jan;59(1):81–7. [PubMed: 20947244]
32.
Dahabreh IJ, Chung M, Balk EM, et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med. 2012 Apr 17;156(8):582–90. [PubMed: 22351515]
33.
Cheng L, Montironi R, Bostwick DG, et al. Staging of prostate cancer. Histopathology. 2012 Jan;60(1):87–117. [PubMed: 22212080]
34.
Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct;56(4):659–67. [PubMed: 19304372]
35.
Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol. 2008 Jun;179(6):2207–10. discussion 10-1. [PMC free article: PMC4270351] [PubMed: 18423693]
36.
Huang Y, Isharwal S, Haese A, et al. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. BJU Int. 2011 May;107(10):1562–9. [PMC free article: PMC3082635] [PubMed: 20875091]
37.
Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1;117(13):2883–91. [PMC free article: PMC3139725] [PubMed: 21692049]
38.
Hinnen KA, Roeloffzen EM, Battermann JJ, et al. Survival after prostate brachytherapy in patients aged 60 years and younger. BJU Int. 2011 June;107(12):1906–11. [PubMed: 21062393]
39.
Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999 Dec 1;59(23):5975–9. [PubMed: 10606244]
40.
Durand X, Moutereau S, Xylinas E, et al. Progensa PCA3 test for prostate cancer. Expert Rev Mol Diagn. 2011 Mar;11(2):137–44. [PubMed: 21405964]
41.
Makarov DV, Loeb S, Getzenberg RH, et al. Biomarkers for prostate cancer. Ann Rev Medicine. 2009;60:139–51. [PubMed: 18947298]
42.
de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002 May 1;62(9):2695–8. [PubMed: 11980670]
43.
Meng FJ, Shan A, Jin L, et al. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):305–9. [PubMed: 11895882]
44.
Day JR, Jost M, Reynolds MA, et al. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 2011 Feb 1;301(1):1–6. [PubMed: 21093148]
45.
de la Taille A. Progensa PCA3 test for prostate cancer detection. Expert Rev Mol Diagn. 2007 Sep;7(5):491–7. [PubMed: 17892357]
46.
Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003 Jul;44(1):8–15. discussion 15-6. [PubMed: 12814669]
47.
Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006 Jun;52(6):1089–95. [PubMed: 16627561]
48.
Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008 Mar;389(1-2):1–6. [PubMed: 18061575]
49.
Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005 Jul 6;294(1):66–70. [PubMed: 15998892]
50.
Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993 Aug 18;270(7):860–4. [PubMed: 7688054]
51.
Sokoll LJ, Witte DL, Klee GG, et al. Redesigned proficiency testing materials improve survey outcomes for prostate-specific antigen. Arch Pathol Lab Med. 2000;124:1608–13. PMID: [PubMed: 11079010]
52.
Schreiber WE, Endres DB, McDowell GA, et al. Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. Arch Pathol Lab Med. 2005;129:331–337. PMID: [PubMed: 15737027]
53.
Garg UC, Howanitz JH, Nakamura RM, et al. Production, analysis, and characterization of reference materials for prostate-specific antigen. Arch Pathol Lab Med. 1995;119:1104–08. PMID: [PubMed: 7503657]
54.
Klee GG, Schryver PG, Kisabith RM. Analytic bias specifications based on the analysis of effects on performance of medical guidelines. Scand J Clin Lab Invest. 1999;59:509–12. PMID: [PubMed: 10667688]
55.
Westgard JO, Westgard SA. An assessment of metrics for analytic quality using σ performance data from proficiency testing surveys and the CLIA criteria for acceptable performance. Am J Clin Pathol. 2006;125:343–54. PMID: [PubMed: 16613337]
56.
Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Sci World J. 2010;10:1919–31. [PMC free article: PMC5763794] [PubMed: 20890581]
57.
Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005 Sep;48(3):386–99. discussion 98-9. [PubMed: 15982797]
58.
Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006 Apr;67(4):762–8. [PubMed: 16600352]
59.
Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen densivity; a means of distinguishing benigh prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815–16. PMID: [PubMed: 1371554]
60.
Giannarini G, Scott CA, Moro U, et al. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer? Urol Oncol. 2008 Jul-Aug;26(4):353–60. [PubMed: 18367100]
61.
Kundu SD, Roehl KA, Yu X, et al. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol. 2007 Feb;177(2):505–09. [PubMed: 17222621]
62.
Thanigasalam R, Mancuso P, Tsao K, et al. Prostate-specific antigen velocity (PSAV): a practical role for PSA? ANZ journal of surgery. 2009 Oct;79(10):703–6. [PubMed: 19878164]
63.
Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009 Jan 20;27(3):398–403. [PMC free article: PMC2645854] [PubMed: 19064972]
64.
Vickers AJ, Brewster SF. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol. 2012 Jul 1;5(4):162–68. [PMC free article: PMC3375697] [PubMed: 22712027]
65.
Ankerst DP, Groskopf J, Day JR, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008 Oct;180(4):1303–8. discussion 08. [PubMed: 18707724]
66.
Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998 Dec;160(6 Pt 2):2407–11. [PubMed: 9817393]
67.
Ploussard G, Epstein JI, Montironi R, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol. 2011 Aug;60(2):291–303. [PubMed: 21601982]
68.
D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002 Dec 1;20(23):4567–73. [PubMed: 12454114]
69.
Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012 Mar 15;366(11):981–90. [PMC free article: PMC6027585] [PubMed: 22417251]
70.
Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Aug, 2011. AHRQ Publication No. 10(11)-EHC063-EF. www​.effectivehealthcare​.ahrq.gov/index.cfm​/search-for-guides-reviews-and-reports​/?pageaction=displayproduct&productid=318.
71.
Methods Guide for Medical Test Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Jun, 2012. effectivehealthcare​.ahrq​.gov/ehc/products​/246/558/Methods-Guide-for-Medical-Test-Reviews​_Full-Guide_20120530.pdf.
72.
Jüni P, Holenstein F, Sterne J, et al. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol. 2002 Feb 1;31(1):115–23. [PubMed: 11914306]
73.
Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009 Oct;62(10):1013–20. [PubMed: 19230606]
74.
U.S. Preventive Services Task Force Procedure Manual. Rockville, MD: Agency for Healthcare Research and Quality; Jul, 2008. AHRQ Publication No. 08-051180-EF.
75.
Higgins JPT, Deeks JJ, Altman DG., on behalf of the Cochrane Statistical Methods Group. Special topics in statistics. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. West Sussex, England: Wiley-Blackwell; 2010. pp. 481–529.
76.
Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6(Mar 6):529–36. [PMC free article: PMC1421422] [PubMed: 16519814]
77.
Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983 Mar;39(1):207–13. [PubMed: 6871349]
78.
Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003 Jul 24;349(4):335–42. [PubMed: 12878740]
79.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--Agency for Healthcare Research and Quality and the Effective Health-care Program. J Clin Epidemiol. 2010 May;63(5):513–23. [PubMed: 19595577]
80.
Ruiz-Aragon J, Marquez-Pelaez S. [Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis]. Actas urologicas espanolas. 2010 Apr;34(4):346–55. [PubMed: 20470697]
81.
Auprich M, Haese A, Walz J, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol. 2010 Nov;58(5):727–32. [PubMed: 20619529]
82.
Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008 Nov;54(5):1081–8. [PubMed: 18602209]
83.
Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007 Mar;69(3):532–5. [PubMed: 17382159]
84.
van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007 Feb 1;13(3):939–43. [PubMed: 17289888]
85.
Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004 Aug;64(2):311–5. discussion 15-6. [PubMed: 15302485]
86.
Tinzl M, Marberger M, Horvath S, et al. DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Uroly. 2004 Aug;46(2):182–6. discussion 87. [PubMed: 15245811]
87.
van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 2008 Aug 1;68(11):1215–22. [PubMed: 18500693]
88.
Kusuda Y, Miyake H, Kurahashi T, et al. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction. Urol Oncol. 2011 May 18 [PubMed: 21600799]
89.
Tosoian JJ, Loeb S, Kettermann A, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol. 2010 Feb;183(2):534–8. [PubMed: 20006883]
90.
Adam A, Engelbrecht MJ, Bornman MS, et al. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. BJU Intl. 2011 Apr 20 [PubMed: 21507188]
91.
Aubin SM, Reid J, Sarno MJ, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010 Nov;184(5):1947–52. [PubMed: 20850153]
92.
Auprich M, Augustin H, Budaus L, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int. 2012 Jun;109(11):1627–35. [PubMed: 21939492]
93.
Bollito E, De Luca S, Cicilano M, et al. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy. Anal Quant Cytol Histol. 2012 Apr;34(2):96–104. [PubMed: 22611765]
94.
Cao DL, Ye DW, Zhang HL, et al. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate. 2011 May 15;71(7):700–10. [PubMed: 20957673]
95.
de la Taille A, Irani J, Graefen M, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011 Jun;185(6):2119–25. [PubMed: 21496856]
96.
Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008 Apr;179(4):1587–92. [PubMed: 18295257]
97.
U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data: PROGENSA PCA3 Assay. 2012. www​.accessdata.fda.gov​/cdrh_docs/pdf10/P100033b.pdf.
98.
Ferro M, Bruzzese D, Perdona S, et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta. 2012 Aug 16;413(15-16):1274–8. [PubMed: 22542564]
99.
Goode RR, Marshall SJ, Duff M, et al. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. 2012 May 14 [PubMed: 22585386]
100.
Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010 Jan 1;70(1):10–6. [PubMed: 19708043]
101.
Mearini E, Antognelli C, Del Buono C, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers. 2009 Jun;14(4):235–43. [PubMed: 19489685]
102.
Nyberg M, Ulmert D, Lindgren A, et al. PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population. Scand J Urol Nephrol. 2010 Dec;44(6):378–83. [PubMed: 20961267]
103.
Ochiai A, Okihara K, Kamoi K, et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol. 2011 Mar;18(3):200–5. [PubMed: 21332814]
104.
Ouyang B, Bracken B, Burke B, et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol. 2009 Jun;181(6):2508–13. discussion 13-4. [PMC free article: PMC4372725] [PubMed: 19371911]
105.
Pepe P, Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res. 2011 Dec;31(12):4445–9. [PubMed: 22199313]
106.
Ploussard G, Haese A, Van Poppel H, et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int. 2010 Oct;106(8):1143–7. [PubMed: 20230386]
107.
Rigau M, Morote J, Mir MC, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate. 2010 Dec 1;70(16):1760–7. [PubMed: 20672322]
108.
Roobol MJ, Schroder FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. European urology. 2010 Oct;58(6):475–81. [PubMed: 20637539]
109.
Schilling D, Hennenlotter J, Munz M, et al. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. Urol Int. 2010;85(2):159–65. [PubMed: 20424427]
110.
Wang R, Chinnaiyan AM, Dunn RL, et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer. 2009 Sep 1;115(17):3879–86. [PMC free article: PMC2746943] [PubMed: 19517474]
111.
Wu AK, Reese AC, Cooperberg MR, et al. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Mar;15(1):100–5. [PubMed: 22042252]
112.
Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Euro Urol. 2011 Jan;59(1):96–105. [PubMed: 20980098]
113.
Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 2012 Jul;110(1):43–49. [PubMed: 22221521]
114.
Liss MA, Santos R, Osann K, et al. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. 2011 Oct;29(5):683–8. [PMC free article: PMC3189407] [PubMed: 21152924]
115.
Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008 May;179(5):1804–9. discussion 09-10. [PubMed: 18353398]
116.
Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. European urology. 2011 Mar;59(3):422–9. [PubMed: 21156337]
117.
van Poppel H, Haese A, Graefen M, et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012 Feb;109(3):360–6. [PubMed: 21883822]
118.
Vlaeminck-Guillem V, Devonec M, Colombel M, et al. Urinary PCA3 score predicts prostate cancer multifocality. J Urol. 2011 Apr;185(4):1234–9. [PubMed: 21334023]
119.
Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008 Nov;180(5):1975–8. discussion 78-9. [PubMed: 18801539]
120.
Roddam AW, Hamdy FC, Allen NE, et al. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. BJU Int. 2007 Sep;100(3):514–7. [PubMed: 17542987]
121.
Otto SJ, Moss SM, Maattanen L, et al. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer. 2010 Nov;46(17):3053–60. [PubMed: 21047586]
122.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:17. [PMC free article: PMC1097734] [PubMed: 15840177]
123.
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19;367(3):203–13. [PMC free article: PMC3429335] [PubMed: 22808955]
124.
Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994 Feb 2;271(5):368–74. [PubMed: 7506797]
125.
Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr;179(4):1354–60. discussion 60-1. [PubMed: 18289596]
126.
Jeldres C, Suardi N, Walz J, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol. 2008 Dec;54(6):1306–13. [PubMed: 18083294]
127.
Oon SF, Watson RW, O'Leary JJ, et al. Epstein criteria for insignificant prostate cancer. BJU Int. 2011 Aug;108(4):518–25. [PubMed: 21320276]
128.
Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008 Feb 1;68(3):645–9. [PMC free article: PMC2998181] [PubMed: 18245462]
129.
Shappell SB, Fulmer J, Arguello D, et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009 Feb;73(2):363–8. [PubMed: 18995890]
130.
Wang Y, Sun G, Pan JG, et al. Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2006;9(4):374–8. [PubMed: 16926855]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.8M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...